Oric Pharmaceuticals (ORIC) EBIT (2019 - 2026)
Oric Pharmaceuticals' (ORIC) quarterly EBIT came in at -$39.6 million in Q1 2026, down 21.09% YoY from -$50.2 million in Q1 2025, and down 14.67% on a QoQ basis from -$34.6 million in Q4 2025.
Oric Pharmaceuticals (ORIC) EBIT (2019 - 2026) Analysis & Trends
Oric Pharmaceuticals (ORIC) has 8 years of EBIT data on file, last reported at -$39.6 million in Q1 2026.
- Quarterly EBIT fell 21.09% year-over-year to -$39.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$149.9 million (down 2.24% YoY) and the FY2025 annual result came in at -$143.0 million, changed 0.08% from the prior year.
- EBIT declined to -$39.6 million in Q1 2026, from -$34.6 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$20.7 million in Q2 2022 to a low of -$39.6 million in Q1 2026.
- A 5-year average of -$31.1 million and a median of -$31.4 million in 2023 frame the typical range for EBIT.
- Annual changes were most pronounced in 2024 — EBIT plunged 44.11% — and 2025, when it climbed 12.68%.
- Tracing ORIC's EBIT over 5 years: stood at -$22.1 million in 2022, then tumbled by 42.09% to -$31.4 million in 2023, then fell by 25.91% to -$39.6 million in 2024, then grew by 12.68% to -$34.6 million in 2025, then slipped by 14.67% to -$39.6 million in 2026.
- The last three EBIT figures came in at -$39.6 million (Q1 2026), -$34.6 million (Q4 2025), and -$36.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Oric Pharmaceuticals | 1.44 Bn | 1.44 Bn | - | -45.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -45.30 Mn |
| Mar 31, 2026 | -39.62 Mn |
| Dec 31, 2025 | -34.55 Mn |
| Sep 30, 2025 | -36.67 Mn |
| Jun 30, 2025 | -39.06 Mn |
| Mar 31, 2025 | -32.72 Mn |
| Dec 31, 2024 | -39.57 Mn |
| Sep 30, 2024 | -38.32 Mn |
| Jun 30, 2024 | -36.02 Mn |
| Mar 31, 2024 | -28.99 Mn |
| Dec 31, 2023 | -31.43 Mn |
| Sep 30, 2023 | -28.68 Mn |
| Jun 30, 2023 | -24.99 Mn |
| Mar 31, 2023 | -25.68 Mn |
| Dec 31, 2022 | -22.12 Mn |
| Sep 30, 2022 | -25.69 Mn |
| Jun 30, 2022 | -20.70 Mn |
| Mar 31, 2022 | -23.26 Mn |
| Dec 31, 2021 | -22.81 Mn |
| Sep 30, 2021 | -18.46 Mn |